Virotrap VLP Protein Interaction Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting protein-protein interactions, such as yeast two-hybrid and phage display, face challenges like non-physiological protein exposure, competition among phages, and difficulty in detecting modification-dependent interactions, leading to false positives and sensitivity limitations.
Innovation Solution
The development of a virus-like particle (VLP) system, known as Virotrap, which uses the HIV p55 GAG protein to trap bait proteins and their interacting partners within virus-like particles formed under physiological conditions, allowing for mild extraction and identification of relevant interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If phage display is used to detect protein-protein interactions, then binding proteins can be displayed on the surface of genetic packages, but the proteins are exposed to a non-physiological environment leading to false positives
Solution Approach 1:
The patent uses a soluble dimerizing protein (e.g., streptavidin-biotin system, antibody-antigen pairs, or coiled-coil domains) as an intermediary to induce dimerization of monomeric bait proteins in solution, rather than displaying them on phage surfaces. This intermediary approach allows physiological interaction conditions while maintaining controlled dimerization to trigger complex formation and detection.
Solution Approach 2:
The invention creates a simplified copy of the dimerization function by using small soluble dimerizing proteins or peptide tags instead of the complex phage display system. This copying approach retains the essential function of bringing two proteins together while eliminating the non-physiological aspects of surface display and phage competition.
2Productivity
If yeast two-hybrid system is used, then genetic approaches can identify protein interactions, but fusion proteins must be translocated to the nucleus which is not always evident and may cause false positives
Solution Approach 1:
The patent extracts the core function of the yeast two-hybrid system (detecting protein-protein interactions) and removes it from the nuclear environment. By performing dimerization-induced complex formation in soluble cytoplasmic or extracellular conditions using small soluble proteins instead of nuclear-localized fusion proteins, the method eliminates translocation requirements and reduces false positives associated with nuclear environment artifacts.
Solution Approach 2:
The invention changes the physical and chemical parameters of the interaction detection system by using soluble proteins at physiological concentrations in appropriate buffers, rather than requiring nuclear translocation and overexpression of fusion proteins. This parameter change maintains interaction detection capability while improving reliability.
3Adaptability or versatility
If modification-dependent interactions are detected using co-expression of modifying enzymes, then such interactions can be identified, but the enzyme may modify other enzymes affecting host viability
Solution Approach 1:
The patent performs preliminary biochemical modification of proteins in vitro before the interaction detection step, rather than co-expressing modifying enzymes with the interaction partners. This preliminary action allows controlled modification of specific proteins of interest without the risk of uncontrolled modification of other cellular proteins that would affect host viability.
Solution Approach 2:
The invention uses purified modifying enzymes or chemical reagents as intermediaries to perform specific modifications on isolated proteins in controlled buffer conditions, rather than relying on endogenous cellular enzymes. This intermediary approach ensures specificity and avoids off-target effects that would compromise host cell survival.
4Productivity
If overexpression of interaction partners is used in genetic systems, then interactions can be detected, but artificial increase in concentration may result in false positives
Solution Approach 1:
The patent uses physiological concentrations of proteins in controlled buffer conditions, rather than overexpression. By optimizing protein concentrations to match native levels and using soluble conditions that promote natural interaction kinetics, the method achieves detection sensitivity without the artifacts caused by artificial overexpression.
Solution Approach 2:
The invention creates a simplified in vitro system that copies the essential features of native protein interactions (physiological concentrations, appropriate buffer conditions, controlled dimerization) without the complications of cellular overexpression machinery, thereby eliminating false positives from artificial concentration increases.
Data Source
Figure 1~2
Figure 3
Figure 4A~4D
AI summary
The present invention relates to a virus-like particle, in which a protein complex is entrapped, ensuring the formation of the protein complex under physiological conditions, while protecting said protein complex during purification and identification. The invention relates further to the use of such virus like particle for the isolation and identification of protein complexes.